Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 05/18/16 → 03/8/20 |
Funding
- Cascadian Therapeutics Incorporated: $38,495.00
Seattle Genetics: Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced of Metastatic HER2+ Breast Carcinoma
- Stopeck, Alison (PI)
- Baer, Lea (CoPI)
- Cohen, Jules (CoPI)
- Kudelka, Andrzej (CoPI)
Project: Research